Abstract
BackgroundTo analyse the differences in computed tomography (CT) features between patients with lung adenocarcinoma who have epidermal growth factor receptor (EGFR) mutations and those who have wild-type EGFR.MethodsPatients with lung adenocarcinoma (n = 156) were enrolled from October 2013 to March 2016, including 56 patients with wild-type EGFR and 100 patients with EGFR mutations. Two independent radiologists evaluated patient characteristics and imaging features. Chi-squared test, Fisher’s exact test or ANOVA was applied to discriminate clinical and CT characteristics between the genotypes. A prediction tool for EGFR mutation was devised from principal component analysis.ResultsThe proportion of females and non-smokers in the exon 19 deletion and exon 21 missense groups was higher than in the wild-type group (P < 0.01). Severe emphysema was higher in the wild-type group than in the exon 19 deletion group (P < 0.01). The maximum diameter in the mediastinal window (MaxDmediastinal) in the wild-type group was longer than in the exon 19 deletion and exon 21 missense groups. The minimum diameter in the mediastinal window (MinDmediastinal) in the wild-type group was also longer than in the exon 21 missense group, with a significant difference (P < 0.05). The tumor shadow disappearance rate (TDR) in the exon 19 deletion group was higher than in the wild-type group. Ground glass opacity (GGO) appeared to be more common in the exon 19 deletion group (P = 0.010). The prediction score for exon 19 deletion mutation was: 0.305 × gender + 0.254 × smoking history + 0.198 × MaxDmediastinal + TDR × 0.254 + 0.280 × GGO + 0.095 × emphysema. The sensitivity and specificity for predicting exon 19 deletion were 59.09 and 76.79%, respectively. The prediction score for the exon 21 missense mutation was: 0.354 × gender + 0.291 × smoking history + 0.410 × MaxDmediastinal + 0.408 × MinDmediastinal. The sensitivity and specificity for predicting exon 21 missense mutation were 72.34 and 78.57%, respectively.ConclusionAs well as gender, smoking history and GGO, adenocarcinomas with EGFR mutation were significantly associated with emphysema, TDR, and the diameter in the mediastinal window. As exon 19 deletion and 21 missense mutations might be predicted by those features, the scoring system might be valuable for clinical diagnosis.
Highlights
Lung and bronchus cancer is the leading cause of cancerrelated deaths worldwide, with an approximate 0.16 million deaths in the United States annually [1], and 0.61 million deaths per year in China [2]
There were no differences in age or tumor stage between wild-type and subtype of EGFRmutant lung adenocarcinomas (Table 1)
We evaluated the differences in various clinical features and computed tomography (CT) features between different genotypes in lung adenocarcinoma
Summary
Lung and bronchus cancer is the leading cause of cancerrelated deaths worldwide, with an approximate 0.16 million deaths in the United States annually [1], and 0.61 million deaths per year in China [2]. EGFR mutations with exon 19 deletions and L858R point mutation in exon 21 occur most frequently in NSCLC, and have a high response rate of approximately 70% to EGFR tyrosine kinase inhibitor (TKI) therapy [4, 6, 8, 9]. Some uncommon point mutations such as exon 21 (at L861) and exon 18 (at G719) were found to have a response rate to EGFR-TKI therapy of approximately 50% [11, 13]. To analyse the differences in computed tomography (CT) features between patients with lung adenocarcinoma who have epidermal growth factor receptor (EGFR) mutations and those who have wild-type EGFR. The maximum diameter in the mediastinal window ( MaxDmediastinal) in the wild-type group was longer than in the exon 19 deletion and exon 21 missense groups. Ground glass opacity (GGO) appeared to be Radiology Department, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
